Navigation Links
Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention

Study results from two research papers have shown that use of the drug Ospemifene in combination with other anti-estrogens for vaginal atrophy reduces the incidence of breast cancer. // The study has been proved in mouse model and researchers are planning for a clinical trial.

DeGregorio and his colleagues at UC Davis compared the ability of ospemifene, tamoxifen and raloxifen to inhibit breast cancer in mice exposed to a carcinogen. Ospemifene and tamoxifen both inhibited breast cancer development. Results show that the mice in the ospemifene group were 95 percent less likely than mice in the control group to develop breast cancer and the study result is to be published in the Journal of Steroid Biochemistry and Molecular Biology.

The second study in which the first study author DeGregorio is also a co-author was led by Jeffrey P. Gregg, Associate professor of pathology and laboratory medicine at UC Davis, where they reported that Tamoxifen and Ospemifene both inhibited the growth and progression of pre-malignant breast lesions that closely resemble human ductal carcinomas in situ in mouse model.

Ospemifene is a Selective Estrogen Receptor Modulator (SERM), and is an effective anti-estrogen like tamoxifen and raloxifen which is used in the prevention and treatment of breast cancer which binds to estrogens. Ospemifene is now being developed by QuatRx Pharmaceuticals, an Ann Arbor, Mich.-based biopharmaceutical company that recently merged with Hormos Medical Corp. The drug is expected to enter Phase 3 clinical testing in the United States early next year for the treatment of vaginal atrophy, a common condition among postmenopausal women.

The advantage of Ospemifene over tamoxifen and raloxifen is due to its reduced side effects as raloxifen can cause hot flashes, insomnia and blood clots. Tamoxifen can cause endometrial cancer in patients undergoing tamoxifen therapy for breast cancer. But ospemifene have a unique estrogen-l ike effect on the vagina, yet a neutral effect on the endometrium, or lining of the uterus, and no aggravation or initiation of hot flashes.
'"/>




Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. Increased Risk Of HIV Transmission Following Vaginal Washing
5. Risk Of AIDS Rises With Vaginal Washes
6. Vaginal massage during pregnancy avoids Episiotomy procedure
7. Vaginal Gel That Protects Against HIV To Hit The Markets By 2010
8. Vaginal Delivery Should Be an Option after Multiple Cesareans
9. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
10. Extra Vaginal Bleed After ‘C’ Section Can be Prevented By Contraceptive Pils
11. Risk of Hemorrhage Increased in Vaginally Born Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/23/2017)... The Woodlands, Texas (PRWEB) , ... August 23, 2017 , ... ... the leading denied claims firms in Texas. Founded by Bill Voss, the firm grew ... over a decade and a half of helping clients get the money they deserve ...
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup ... of health IT to create efficiencies in healthcare information exchange and a trusted advisor ... Summer Forum which featured keynote addresses by Donald W. Rucker, MD, head of ...
(Date:8/23/2017)... , ... August 23, 2017 , ... The Stevie® Awards have announced the winners of ... , the world’s premier business awards competition. , Nominees in the 2017 IBAs were not ... a points system based on the total number of awards won in the IBAs with ...
(Date:8/23/2017)... FL (PRWEB) , ... August 23, 2017 , ... ... for traveling medical professionals, recently launched a new website, http://www.cirrusmedicalstaffing.com . The ... to respond to the needs of healthcare professionals who are traveling on short-term ...
(Date:8/23/2017)... ... August 23, 2017 , ... MobilityWorks ®, the ... to the 2017 Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. ... 139 percent, marking the twelfth year that the company has been included on ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... WARSAW, Ind. , Aug. 7, 2017 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the third quarter of 2017. ... will be paid on or about October 27, 2017 to ... September 22, 2017.  Future declarations of dividends are subject to ...
(Date:8/7/2017)... 2017  Endo International plc (NASDAQ: ENDP ... virtually all known U.S. mesh product liability claims and ... known remaining U.S. claims at reasonable values. Under the ... fourth quarter of 2017 and continuing through the fourth ... 2017 results, the Company intends to increase its mesh ...
Breaking Medicine Technology: